LVTX — LAVA Therapeutics NV Income Statement
0.000.00%
Last trade - 00:00- $33.67m
- -$40.33m
- $11.98m
- 62
- 24
- 19
- 27
Annual income statement for LAVA Therapeutics NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 10-K | 10-K |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.5 | 5 | 19.4 | 6.77 | 12 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 3.29 | 12 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 18.4 | 49.4 | 54.2 | 50.2 | 41.7 |
| Operating Profit | -14.9 | -44.4 | -34.8 | -43.4 | -29.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -15.5 | -45.2 | -31.7 | -41.6 | -24.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15.5 | -45.3 | -31.9 | -41.9 | -25.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.5 | -45.3 | -31.9 | -41.9 | -25.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.5 | -45.3 | -31.9 | -41.9 | -25.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.612 | -2.3 | -1.23 | -1.57 | -0.936 |